AGTC Stock : The shares of the biopharmaceutical firm in the clinical stage Applied Genetic Technologies Corporation (AGTC) increased by 23% on the day following an enormous increase in volume since AGTC signed a large partnership with the biotech company Biogen (BIIB -2.11 0.1%) to create multiple therapies for the treatment of rare eye diseases. According to the agreements, Biogen will pay $124 million in upfront payments, which include the investment of $30 million into Applied Genetic shares . If any product makes it to commercialization, Applied Genetic would also be eligible for royalty payments ranging from single-digits up to mid-teens in percentage on net sales per year.
Applied Genetic Technologies Returns vs. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| AGTC | -81.86% | -89.64% | -36.46% | -97% |
| S&P | -14.41% | +42.63% | +7.36% | +112% |
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $34.24M | -62.2% |
| Accounts Receivable | – | – |
| Inventory | 0 | – |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $9.34M | -50.5% |
| Short Term Debt | $10.81M | +94.2% |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -83.7% | +37.8% |
| Return On Invested Capital | -59.8% | +126.6% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$15.98M | -1.9% |
| Operating Free Cash Flow | -$15.79M | +0.3% |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | 1.17 | 0.89 | 0.83 | 0.47 | -68.7% |
| Price to Sales | 162.97 | 93.39 | 120.73 | 54.25 | -79.0% |
| Price to Tangible Book Value | 1.19 | 0.92 | 0.86 | 0.49 | -67.6% |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | -1.86 | -0.26 | -0.89 | -0.21 | -94.7% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | -136.0% | -87.1% | -119.6% | -161.1% | +70.1% |
| Total Debt | $24.63M | $24.56M | $22.47M | $20.15M | -17.6% |
